Voluntis: Results of the eCO Trial Published in the Journal of Clinical Oncology Informatics
Summary
The eCO app was specifically designed to assist in managing acute treatment-related events such as hypertension and diarrhea, which are most often associated with treatment discontinuation, the need for drug holidays or dose interruptions/modifications. We believe that digital therapeutics will one day become part of routine clinical oncology practice.” AstraZeneca and Voluntis formed a partnership in 2015, in collaboration with the NCI, to develop an innovative digital solution to support women undergoing treatment for recurrent platinum-sensitive high-grade ovarian cancer in clinical trials of cediranib plus olaparib. Voluntis creates digital therapeutics that empower people suffering from chronic conditions to self-manage their treatment every day, thus improving real-world outcomes. Combining mobile and web apps, Voluntis’ solutions deliver personalized recommendations to the patient and the care team that so that they can, for example, adjust treatment dosage, manage side effects or monitor symptoms. AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory.
Classifications
AskAI Classifications
LabelsLinked Companies
